NCT01335165View on ClinicalTrials.gov

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

ALXN1102

Single Ascending Dose IV

DRUG

ALXN1103

Single Ascending Dose IV or SC

Trial Locations (5)

80131

Federico II University of Naples, Via Pansini 5

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

128 08

Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze, U Nemocnice 1

80-952

University Clinical Centre, Dębinki

SE5 9RS UK

King's College Hospital NHS Foundation Trust, Denmark Hill

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY